👩‍🔬 Putting science into practice, strategic collaborations and learning from experts during our EUROGIN 2025 visit in Porto. Our Chief Scientific Officer Jolien de Waard shared the scientific highlights of our work during two great presentations. With 1600+ international participants from 78 different countries this is the platform to share our clinical validation data and let the world know about our Methica CC kit superior performance. The feedback is well received and we’re very excited about the follow-up and implementation projects. 

🎉We’re thrilled to announce that CC Diagnostics was selected as one of 30 trailblazing European start-ups in the prestigious EIT Catapult! With this program's support, we’re more energized than ever to advance cervical cancer screening and make a global impact on women’s healthcare.

CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? 97% sensitivity for cancer detection, outperforming the pap smear by 21%—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.